中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
23期
43-46
,共4页
吴鹏%徐佳佳%王国庆%冯俊志%施风
吳鵬%徐佳佳%王國慶%馮俊誌%施風
오붕%서가가%왕국경%풍준지%시풍
非小细胞肺癌%吉西他滨%化疗敏感性%原代细胞
非小細胞肺癌%吉西他濱%化療敏感性%原代細胞
비소세포폐암%길서타빈%화료민감성%원대세포
Non-small cell lung cancer%Gemcitabine%Chemosensitivity%Primary culture cell
目的:探讨非小细胞肺癌(NSCLC)吉西他滨(GEM)化疗敏感性预测靶标。方法30例NSCLC组织,体外药敏试验明确GEM IC50值;Realtime-PCR检测GEM代谢酶hENT1、dCK、RRM1和RRM2 mRNA表达水平。结果 hENT1、dCK、RRM1和RRM2单个基因表达量与GEM IC50值无关(P>0.05);(hENT1×dCK)/(RRM1×RRM2)值与GEM IC50值呈负相关(P<0.001)。结论(hENT1×dCK)/(RRM1×RRM2)值可作为GEM化疗敏感性预测的潜在标志物。
目的:探討非小細胞肺癌(NSCLC)吉西他濱(GEM)化療敏感性預測靶標。方法30例NSCLC組織,體外藥敏試驗明確GEM IC50值;Realtime-PCR檢測GEM代謝酶hENT1、dCK、RRM1和RRM2 mRNA錶達水平。結果 hENT1、dCK、RRM1和RRM2單箇基因錶達量與GEM IC50值無關(P>0.05);(hENT1×dCK)/(RRM1×RRM2)值與GEM IC50值呈負相關(P<0.001)。結論(hENT1×dCK)/(RRM1×RRM2)值可作為GEM化療敏感性預測的潛在標誌物。
목적:탐토비소세포폐암(NSCLC)길서타빈(GEM)화료민감성예측파표。방법30례NSCLC조직,체외약민시험명학GEM IC50치;Realtime-PCR검측GEM대사매hENT1、dCK、RRM1화RRM2 mRNA표체수평。결과 hENT1、dCK、RRM1화RRM2단개기인표체량여GEM IC50치무관(P>0.05);(hENT1×dCK)/(RRM1×RRM2)치여GEM IC50치정부상관(P<0.001)。결론(hENT1×dCK)/(RRM1×RRM2)치가작위GEM화료민감성예측적잠재표지물。
Objective To explore biomarker of Gemcitabine (GEM) chemosensitivity in non-small cell lung cancer (NSCLC). Methods GEM IC50 of 30 NSCLC tissues were detected by susceptibility testing in vitro, mRNA expression of hENT1, dCK ,RRM1 and RRM2 were determined by Realtime-PCR. Results hENT1, dCK, RRM1 or RRM2 expression levels in individual gene had no relationship with the GEM IC50 value (P > 0.05), however, ratio of (hENT1ídCK)/(RRM1íRRM2) was negatively correlated with GEM IC50 value (P < 0.001). Conclusion Ratio of (hENT1ídCK)/(RRM1íRRM2) may predict GEM chemosensitivity in NSCLC.